How does this study impact clinical practice?

• Eptinezumab provides rapid and sustained migraine relief for patients who experience both episodic and chronic migraine.
• Eptinezumab prevents the occurrence of migraine from day one following intravenous administration and is sustained for up to 12 weeks in the majority of patients.